Skip to content

Evaluation and comparison of ketamine-dexmedetomidine versus ketamine-propofol in post operative mechanically ventilated patients

A Study to compare safety and efficacy of ketamine-dexmedetomidine versus ketamine-propofol in post operative mechanically ventilated patients - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/04/085026
Enrollment
70
Registered
2025-04-17
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: O- Medical and Surgical

Interventions

Intervention1: continuous intravenous sedation in post operative mechanically ventilated patients with ketamine dexmedetomidine combination: Post operative patients shifted to ICU for elective mechani

Sponsors

Pt B D Sharma PGIMS
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Post operative patients between 18-60 years of age, intubated and shifted to ICU for a period of 12 to 24 hours 2)Afebrile 3)Hemodynamically stable

Exclusion criteria

Exclusion criteria: 1)Pateint less than 18 years of age 2)patient with hypotension, Bradycardia, metabolic acidosis. 3)patients with head injury 4)patients requiring neuromascular blocking agents along with sedation 5)pregnancy 6)neurological disease or injury 7)liver or renal insufficiency 8)intraoperative or post operative hemodynamic instability 9)patients on vasopressor or ionotropic support 10)patients with metabolic derangements 11)patients receiving epidural or any other type of analgesia apart from the standardized analgesia used in study

Design outcomes

Primary

MeasureTime frame
1)modified RASS score 2)Nonverbal pain score 3)adverse effectsTimepoint: 1)Modified RASS score will be assessed at starting of infusion(0hr),1Hr,6Hr,12hr and 24hrly 2)nonverbal pain score will be assessed at starting of infusion(0hr),1hr,6hr,12hr and 24hr 3)adverse effects will be assessed at any time during continuous intravenous infusion

Secondary

MeasureTime frame
1)Recovery time 2)duration of weaningTimepoint: R time of stopping of infusion [T1] to time of return of full consciousness[T2] is recovery time will be assessed after stopping of infusion. 2)duration of weaning is that Time of start of spontaneous breathing trial[T3] to time of extubation [T4]

Countries

India

Contacts

Public ContactDr Vignesh P

Department of Anaesthesiology and Critical care

chhikara.monica@gmail.com9468465746

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026